These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 30701603)

  • 1. A Safe-by-Design Strategy towards Safer Nanomaterials in Nanomedicines.
    Yan L; Zhao F; Wang J; Zu Y; Gu Z; Zhao Y
    Adv Mater; 2019 Nov; 31(45):e1805391. PubMed ID: 30701603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Toxicological Considerations of Nanomedicines: The Future Directions.
    Patel P; Shah J
    Curr Clin Pharmacol; 2017; 12(2):73-82. PubMed ID: 28486906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brave new world revisited: Focus on nanomedicine.
    Fadeel B; Alexiou C
    Biochem Biophys Res Commun; 2020 Nov; 533(1):36-49. PubMed ID: 32921412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanomaterials meet zebrafish: Toxicity evaluation and drug delivery applications.
    Jia HR; Zhu YX; Duan QY; Chen Z; Wu FG
    J Control Release; 2019 Oct; 311-312():301-318. PubMed ID: 31446084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety Assessment of Nanomaterials for Antimicrobial Applications.
    Ali A; Ovais M; Cui X; Rui Y; Chen C
    Chem Res Toxicol; 2020 May; 33(5):1082-1109. PubMed ID: 32302095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Nano-Bio Interactions of Nanomedicines: Understanding the Biochemical Driving Forces and Redox Reactions.
    Wang Y; Cai R; Chen C
    Acc Chem Res; 2019 Jun; 52(6):1507-1518. PubMed ID: 31149804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of nanomedicine in cardiovascular diseases and stroke.
    Kim KS; Khang G; Lee D
    Curr Pharm Des; 2011; 17(18):1825-33. PubMed ID: 21631424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibacterial nanomedicine.
    Yacoby I; Benhar I
    Nanomedicine (Lond); 2008 Jun; 3(3):329-41. PubMed ID: 18510428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Advances in Managing Atherosclerosis via Nanomedicine.
    Chan CKW; Zhang L; Cheng CK; Yang H; Huang Y; Tian XY; Choi CHJ
    Small; 2018 Jan; 14(4):. PubMed ID: 29239134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory safety evaluation of nanomedical products: key issues to refine.
    De Jong WH; Geertsma RE; Borchard G
    Drug Deliv Transl Res; 2022 Sep; 12(9):2042-2047. PubMed ID: 35908133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysosomal nanotoxicity: Impact of nanomedicines on lysosomal function.
    Uzhytchak M; Smolková B; Lunova M; Frtús A; Jirsa M; Dejneka A; Lunov O
    Adv Drug Deliv Rev; 2023 Jun; 197():114828. PubMed ID: 37075952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inorganic nanomaterials with rapid clearance for biomedical applications.
    Wang X; Zhong X; Li J; Liu Z; Cheng L
    Chem Soc Rev; 2021 Aug; 50(15):8669-8742. PubMed ID: 34156040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Nano-safety science for assuring the safety of nanomaterials].
    Yoshioka Y; Yoshikawa T; Tsutsumi Y
    Nihon Eiseigaku Zasshi; 2010 Sep; 65(4):487-92. PubMed ID: 20885074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opportunities and Challenges for Inhalable Nanomedicine Formulations in Respiratory Diseases: A Review.
    Feng X; Shi Y; Zhang Y; Lei F; Ren R; Tang X
    Int J Nanomedicine; 2024; 19():1509-1538. PubMed ID: 38384321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro toxicity assessment of oral nanocarriers.
    Ciappellano SG; Tedesco E; Venturini M; Benetti F
    Adv Drug Deliv Rev; 2016 Nov; 106(Pt B):381-401. PubMed ID: 27544694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine.
    Zhang XQ; Xu X; Bertrand N; Pridgen E; Swami A; Farokhzad OC
    Adv Drug Deliv Rev; 2012 Oct; 64(13):1363-84. PubMed ID: 22917779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lignin, lipid, protein, hyaluronic acid, starch, cellulose, gum, pectin, alginate and chitosan-based nanomaterials for cancer nanotherapy: Challenges and opportunities.
    Carrion CC; Nasrollahzadeh M; Sajjadi M; Jaleh B; Soufi GJ; Iravani S
    Int J Biol Macromol; 2021 May; 178():193-228. PubMed ID: 33631269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disposition and safety of inhaled biodegradable nanomedicines: Opportunities and challenges.
    Haque S; Whittaker MR; McIntosh MP; Pouton CW; Kaminskas LM
    Nanomedicine; 2016 Aug; 12(6):1703-24. PubMed ID: 27033834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanotechnology in Drug Delivery: Safety and Toxicity Issues.
    Jain K; Mehra NK; Jain NK
    Curr Pharm Des; 2015; 21(29):4252-61. PubMed ID: 26323425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in green nanoparticulate systems for drug delivery: efficient delivery and safety concern.
    Lam PL; Wong WY; Bian Z; Chui CH; Gambari R
    Nanomedicine (Lond); 2017 Feb; 12(4):357-385. PubMed ID: 28078952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.